For 2018, there are an estimated 1,735,350 new cancer cases diagnoses and 609,640 projected cancer death in the United States, of which 268,670 are attributed to breast cancer with 41,400 deaths. Patient survival rate and prognosis depends on the type of cancer, in which, highly aggressive and invasive carcinomas promote the most mortality. In men, prostate cancer is the leading cause of all cancer among men (19%), followed by lung cancer (14%), and colon and rectum cancer (9%). In women, breast cancer is the forefront leading cause of all cancer among women (30%), followed by lung cancer (13%), and colon and rectum cancer (7%). Additionally, in the United States, breast cancer afflicts 1 in 8 women during their lifetime, this high prevalence provides evidence for the need to foster new therapeutic interventional research. While many approved drugs are well-tolerated by most biological systems, numerous drugs could utilize advanced delivery systems to direct them where needed and minimize breakdown as they circulate through the body. A major problems in cancer chemotherapy is the deleterious side effects of anticancer drugs designed to destroy rapidly dividing cells, including those found in healthy tissues. Due to these severe side effects, doctors often resort to dose reduction, treatment delay or discontinuance of therapy. To combat this problem, we have explored targeted delivery of various chemotherapeutics using Luteinizing hormone-releasing hormone (LHRH). We have synthesized Pt-Mal-LHRH, a Carboplatin analog which selectively targets cancer cells and attenuates breast cancer tumor growth. Data on potency and selectivity of Pt-Mal-LHRH will be discussed.<br/>

Pt-Mal-LHRH attenuates breast cancer tumor growth and metastasis by targeting overexpression of the LHRH receptor

2019 Spring National Meeting

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.